Availability may vary, so calling ahead is wise
Although research is currently limited, Anna talks about what we know so far and her experience with clients taking these drugs in clinical practice
That includes muscle, which plays a direct role in everything from insulin sensitivity to mobility and fall risk
Apply the same evidence-based monitoring framework as for all semaglutide preparations: HbA1c reduction (typical ~1.5% for T2DM), body weight reduction (~15% for obesity), and cardiovascular outcome benefit in patients with T2DM and established CVD (consistent with SUSTAIN-6 data)
(2) Ps-graduao em Cincias Mdicas, Universidade Federal Fluminense, Niteri, RJ, Brasil Diabetology & Metabolic Syndrome 2026: PO207 Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among individuals with type 2 diabetes mellitus (T2DM), reflecting the strong association between insulin resistance and hepatic fat accumulation